Leukemia section

Leukemia News and Features

Risk of Relapse Up for Young Adults With Leukemia

Risk of Relapse Up for Young Adults With Leukemia

Increased risk of on-therapy relapse, relapse after completing therapy versus children with ALL

FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia

FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia

Lumoxiti, a CD22-directed cytotoxin, has been approved for adult patients who have had at least two prior therapies for the disease.

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.

Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL

Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL

Ibrutinib monotherapy may reduce the need for chemotherapy for some treatment-naive patients with chronic CLL, research indicates.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs